

# SERUM EXCHANGE #558 SEPTEMBER 28, 2017

Sera	1225-1228
------	-----------

The results for **Serum Exchange 558 (sera 1225 - 1228)**, are summarized in Tables 16 -23 and individual laboratory results by method are listed in

Tables 24-34. Sera strongly positive to B44, B45, and 5C specificities were examined in this study.

1225		method	#labs	B35	B53	B49	B44	B45	B62	B51	B50	B72	B75	B78	B60	B61	B13	A24	2403	B63	B41	B47	B52	B46	B42	B39	B3901	B56	B18	B37	B38	B48	B54	B55		
class I	NIH-Std	2	100	100	50	50	50	50	50	50																										
	NIH-Ext	2	50	50	100	50	50	100	50	100	50	50	50		50																					
	AHG	5	80	80	80	80	100	80	60	80	60	60	60	60	40	60	80	40		40	40	40	40	40	40	40		40	20	20	20	20	20	20	20	
	Luminex	29	100	100	100	100	100	97	93	100	97	97	93	97	93	97	83	28	97	97	93	93	86	48	76	28	100	97	93	93	93	79	86	93		
	ELISA	1	no consensus																																	
	Flow	1	no specificities assigned																																	
	C1q	2	100	100	100		50	100	100	100	100		50		100	50																				
	Other	3	33	33	33	33	33	33	33	33	33	33	33										33					33								

  

1225		method	#labs	A2	A203	A23	A29	A25	A34	A43	A66	A6601	A68	A69	B71	B70	A26	B57	B58	B76	B77	B59	B67	B64	B65	B8	Cw4	Cw9	Cw10	Cw15	Cw5	Cw14	Cw1		
class I	NIH-Ext	2													50	50											50								
	AHG	5	20		20	20	20	20	20	20	20		20	20			20																		
	Luminex	29	55	21	69	31	38	31	34	24	21	45	55	97			97	97	97	97	93	83	79	55	66	52	66	66	45	31	24	21			
	C1q	2												100																					
	Other	3	33												33																				

**Serum 1225** was reported as strongly positive to B35, B49, and B53 by all methods. Anti-B44, -B45, -B51, and -B62 reactivity was also reported by a number of methods. In addition, reactivity to A9 (A23, A24), B16 (B38, B39), 7C, and 10C specificities was also reported by Luminex and antiglobulin. Arnold noted “serum #1225(Green) appears to bind all Bw4 beads except A25, A32, and B\*27:05. Interestingly, while most Bw4 epitopes have an asparagine at position 77, these three antigens have either a serine or aspartic acid at position 77, which may not be recognized by this particular Bw4 antibody.” Allele specific A\*34:01 reactivity was detected by several Luminex labs. Class II reactivity was also detected in this cell, with Luminex and 1 antiglobulin lab reporting

1225		method	#labs	DR17	DR18	DR13	DR52	DR14	DQ2	DR11	DR12	DPw6	DQA1*05	DR1404	DQ4	NEG
class II	NIH-Ext	1	no antigens assigned													
	AHG	1	100	100	100	100	100	100	100							
	Luminex	27	93	93	72	72	59	37	26	19	11	11	11	11	7	
	Flow	1	no specificities assigned													
	C1q	2	NT													
	Other	2	50	50												

reactivity to DR17 and DR18. Additional reactivity to DR13, DR52, and DR14 was also reported by Luminex.

1226	method	#labs	B44	B45	B49	B50	B13	B41	B47	B60	B61	B76	A23	B39	A34	A1	A24	B62	B71	B72	B46	B82	B35	B73	B75	B78	B18	B64	B48	Cw16	Cw1	Cw10	Cw12	Cw8	Cw9	Cw14	Cw7	B27	B37	B40	B51	B65							
class I	NIH-Std	2	100	100			50																																										
	NIH-Ext	2	100	50	100	100		50																																									
	AHG	5	100	80	80	60	60	40	40	40	40	20	40	40	40	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20		
	Luminex	29	100	100	100	100	100	100	97	97	93	97	55	79	41	72	31	97	97	90	90	90	86	86	79	69	69	76	76	83	79	79	79	76	72	59	41	21	17	10					24				
	ELISA	1	no consensus																																														
	Flow	1	no specificities assigned																																														
	C1q	2	100	100	100	100	100	100	100	100	100	100																																					
	Other	2	50	50	50	50	50	50	50	50	50																																						

1226	method	#labs	DR7	DR9	NEG				
class II	NIH-Ext	1	no antigens assigned						
	AHG	1	100	100					
	Luminex	27	93	93	7				
	Flow	1	no specificities assigned						
	C1q	2	NT						
	Other	2	50	50					

For Serum 1226, strong anti-B44 and –B45 reactivity was reported. Reactivity to B49, B50, and a number of 7C specificities was also reported by various methods. In addition, Luminex and antiglobulin reported reactivity to A1, A23, A24, A34, B39, B64, and reactivity to a number of 5C ad C-locus specificities. For class II, strong DR7 and DR9 reactivity was reported by Luminex and antiglobulin. Interestingly, 2 labs noted this sample as negative for class II.

1227	method	#labs	B51	B35	B50	B71	B72	B62	B18	B75	B78	B53	B52	B63	B49	B37	B45	B77	B46	B56	B38	B8	B39	Cw4	Cw10	Cw9	B76	B54	B48	B73	A33	A66	A68	A69	A26	
class I	NIH-Std	2	100	100					51	50	50																									
	NIH-Ext	2	100	50	100	100	100	100	50	50		50	50											50												
	AHG	5	100	80	60		40	80	80	40	80	80	60	60	40	40	40		40	40	40	40	40							40	40	20	20	20		
	Luminex	29	100	100	100	97	97	97	100	97	90	100	97	97	100	100	100	97	100	100	97	97	86	90	90	90	97	97	90	83	90	83	100	76	66	
	ELISA	1	no consensus																																	
	Flow	1	no specificities assigned																																	
	C1q	2	100	100	100	100	100	100	100	100	100	100	100	100	100	100		100	50	100	50	50	100	100	50	50	100	100	50							
	Other	2	50	50	50	50	50	50	50	50	50	50	50	50	50		50	50											50							
1227	method	#labs	B42	B57	B7	B41	B64	B60	B61	A25	A34	B55	B67	Cw18	Cw6	Cw1	Cw15	Cw14	B58	B65	B59	B3901	B81	A6601	A6602	B82	B27	B2708	B13	Bw6	A31	A36	B47			
class I	AHG	5	60	40	40	40	60	60	40	20	20																					20	20			
	Luminex	29	100	100	100	97	93	93	93	97	93	100	100	66	62	45	34	24	97	97	93	24	86	31	28	83	76	41	52	24				3		

1227	method	#labs	DQ4	DR8	DR12	DR11	DR13	DR14	DR17	DR18	DQ8	DQ9	DQ7	DQ2	DQA1*05	DQA1*06	DQA1*04	DR1404	DQA1*03	DQ3	DR1403	DR3	DR52
class II	NIH-Ext	1	no antigens assigned																				
	AHG	1	100	100	100	100	100	100	100	100	100	100	100										
	Luminex	27	100	100	100	100	100	100	90	90	90	90	50	10	50	40	40	20	20	10	10	10	10
	Flow	1	no specificities assigned																				
	C1q	2	100	100	50																		
	Other	2	50	50	50	50	50	50	50	50	50	50											

**Serum 1227** was found to be strongly positive to B51. Additional strong reactivity to many other 5C specificities was also reported by various methods. In addition, Luminex and antiglobulin reported reactivity to B42, B41, as well as reactivity to 10C specificities. Additional C-locus reactivity (Cw1, Cw6, w14, Cw15, Cw18) was also reported by Luminex. Class II re-

activity to DR8, DR12, and DQ4 was reported by Luminex, antiglobulin, and C1q. Additional reactivity to other DR antigens (DR11, DR13, DR14, DR17, DR18) and DQ antigens (DQ7, DQ8, DQ9) was reported by Luminex and antiglobulin.

1228	method	#labs	B49	B57	B62	B75	B46	B63	A1	B13	B35	B45	B44	B50	B52	B53	B71	B72	A23	A29	A36	A80	A11	A1101	A1102	A25	A26	A34	A43	A66	A6601	B58	B56	B41	B37	B27	B2708	B78		
class I	NIH-Std	2	50	50	50	50																																		
	NIH-Ext	3		100	100	67	67	100	33	33	33								33	33	33	33	33		33	33	33	33	33		67				33					
	AHG	5	80	80	80	60	60	60	40	40	40	40	40	40	40	40	40	40	20	20	20	20	20		20	20	20	20	20				40	20	40	20		40		
	Luminex	29	100	96	96	96	100	96	100	100	100	100	100	100	96	100	96	96	100	100	100	100	86	32	32	93	82	71	100	71	39	100	100	96	96	79	39	89		
	ELISA	1	no consensus																																					
	Flow	1	no specificities assigned																																					
	C1q	2	100	100	100	100	100	100	100	100	100	100	50	100	100	100	100	100	50													100	100	50	50			100		
	Other	2	50		50	50		50			50	50	50	50	50	50	50	50																						

  

1228	method	#labs	B51	B76	B77	B15	B22	B38	B39	B3901	B42	B47	B55	A24	A68	Cw10	Cw5	Cw9	Cw6	Cw18	Cw2	Cw4	Cw17	Cw15	Cw1	Cw14	B67	B59	B82	B61	B60	B48	B54	A33	A31			
class I	NIH-Std	2				50	50																															
	NIH-Ext	3		67											33																							
	AHG	5	40			20	20	20	20		20	20	40																									
	Luminex	29	96	96	96			96	86	25	86	43	100	93	79	89	89	89	96	89	86	86	82	79	64	64	100	86	86	61	46	39	25	46	29			
	C1q	2	100	100	100									50		100		100																				
	Other	2				50																																

1228	method	#labs	DR52	DR17	DR18	DR13	DR14	DR11	DQA1*05	
class II	NIH-Ext	2	50	50	50					
	AHG	1	NT							
	Luminex	26	85	92	92	35	31	27	19	
	Flow	1	no specificities assigned							
	C1q	2	NT							
	Other	2	50							

For **Serum 1228**, reactivity to B62, B57, and B75 was detected. Additional reactivity to other 5C specificities, as well as to A11, B44, B45, 1C, 7C, and 10C specificities was reported by various labs. Reactivity to a number of C-locus antigens was also reported by Luminex. Allele level A\*24:02 reactivity was reported by a number (n = 4) of labs. For class II, anti-DR52, -DR17, and -DR18 reactivity was reported by Luminex and 1 lab reporting by NIH-extended.



**NEXT MAILING DATE: November 8, 2017**

*Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed*



**Table 16. Summary of the 558<sup>th</sup> Serum Exchange (Serum #1225-1228) by NIH-Standard and NIH-Extended - class I**

Method: NIH-Standard											
*** Serum 1225 ***			*** Serum 1226 ***			*** Serum 1227 ***			*** Serum 1228 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B53	100%	100%	B44	100%	100%	B35	100%	100%	B15	50%	100%
B35	100%	58%	B45	100%	100%	B51	100%	100%	B22	50%	100%
B44	50%	100%	B13	50%	100%	B18	50%	100%	B49	50%	100%
B45	50%	100%				B75	50%	100%	B57	50%	100%
B49	50%	100%				B78	50%	100%	B62	50%	100%
B51	50%	100%							B75	50%	100%
B62	50%	40%									

Method: NIH-Extended											
*** Serum 1225 ***			*** Serum 1226 ***			*** Serum 1227 ***			*** Serum 1228 ***		
2 typing Labs			2 typing Labs			2 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B49	100%	100%	B44	100%	100%	B50	100%	100%	B57	100%	100%
B50	100%	100%	B50	100%	100%	B51	100%	100%	B62	100%	100%
B62	100%	100%	B49	100%	67%	B62	100%	100%	B63	100%	100%
B35	50%	100%	B41	50%	100%	B71	100%	100%	B46	67%	100%
B44	50%	100%	B45	50%	100%	B72	100%	100%	B75	67%	100%
B45	50%	100%				B18	50%	100%	B76	67%	100%
B51	50%	100%				B35	50%	100%	B58	67%	67%
B53	50%	100%				B52	50%	100%	A1	33%	100%
B60	50%	100%				B53	50%	100%	A11	33%	100%
B70	50%	100%				B75	50%	100%	A23	33%	100%
B71	50%	100%				Cw4	50%	100%	A25	33%	100%
B72	50%	100%							A26	33%	100%
B75	50%	100%							A29	33%	100%
Cw4	50%	100%							A34	33%	100%
									A36	33%	100%
									A43	33%	100%
									A66	33%	100%
									A68	33%	100%
									A80	33%	100%
									B13	33%	100%
									B27	33%	100%
									B35	33%	100%

**Table 17. Summary of the 558<sup>th</sup> Serum Exchange (Serum #1225-1228) by Antiglobulin - class I**

Method: Antiglobulin											
*** Serum 1225 ***			*** Serum 1226 ***			*** Serum 1227 ***			*** Serum 1228 ***		
5 typing Labs			5 typing Labs			5 typing Labs			5 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B44	100%	100%	B44	100%	100%	B51	100%	100%	B49	80%	100%
B13	80%	100%	B45	80%	100%	B18	80%	100%	B57	80%	100%
B35	80%	100%	B49	80%	100%	B35	80%	100%	B62	80%	100%
B45	80%	100%	B13	60%	100%	B53	80%	100%	B46	60%	100%
B49	80%	100%	B50	60%	100%	B62	80%	100%	B63	60%	100%
B53	80%	100%	A23	40%	100%	B78	80%	100%	B75	60%	100%
B51	80%	82%	B41	40%	100%	B42	60%	100%	A1	40%	100%
B50	60%	100%	B47	40%	100%	B50	60%	100%	B13	40%	100%
B61	60%	100%	B60	40%	100%	B52	60%	100%	B35	40%	100%
B62	60%	100%	B61	40%	100%	B60	60%	100%	B37	40%	100%
B72	60%	100%	B39	40%	75%	B63	60%	100%	B45	40%	100%
B75	60%	100%	A34	40%	50%	B64	60%	100%	B50	40%	100%
B78	60%	100%	A1	20%	100%	B64	60%	100%	B52	40%	100%
A24	40%	100%	B18	20%	100%	A33	40%	100%	B55	40%	100%
B41	40%	100%	B35	20%	100%	A66	40%	100%	B56	40%	100%
B42	40%	100%	B37	20%	100%	B37	40%	100%	B71	40%	100%
B46	40%	100%	B40	20%	100%	B38	40%	100%	B72	40%	100%
B47	40%	100%	B46	20%	100%	B39	40%	100%	B78	40%	100%
B52	40%	100%	B48	20%	100%	B41	40%	100%	B44	40%	89%
B60	40%	100%	B51	20%	100%	B45	40%	100%	B51	40%	89%
B63	40%	100%	B62	20%	100%	B46	40%	100%	B53	40%	83%
B39	40%	75%	B64	20%	100%	B49	40%	100%	A11	20%	100%
B56	40%	60%	B71	20%	100%	B56	40%	100%	A23	20%	100%
A2	20%	100%	B72	20%	100%	B57	40%	100%	A25	20%	100%
A23	20%	100%	B73	20%	100%	B61	40%	100%	A26	20%	100%
A25	20%	100%	B75	20%	100%	B7	40%	100%	A29	20%	100%
A26	20%	100%	B76	20%	100%	B72	40%	100%	A34	20%	100%
A29	20%	100%	B78	20%	100%	B75	40%	100%	A36	20%	100%
A34	20%	100%	B82	20%	100%	B8	40%	100%	A43	20%	100%
A43	20%	100%	Cw1	20%	100%	A25	20%	100%	A66	20%	100%
A66	20%	100%	Cw10	20%	100%	A26	20%	100%	A80	20%	100%
A68	20%	100%	Cw12	20%	100%	A31	20%	100%	B15	20%	100%
A69	20%	100%	Cw14	20%	100%	A34	20%	100%	B22	20%	100%
B18	20%	100%	Cw16	20%	100%	A36	20%	100%	B27	20%	100%
B37	20%	100%	Cw7	20%	100%	A68	20%	100%	B38	20%	100%
						A69	20%	100%			

**Table 18. Summary of the 558<sup>th</sup> Serum Exchange (Serum #1225-1228) by Other and Flow Cytometry - class I**

Method: Other											
*** Serum 1225 ***			*** Serum 1226 ***			*** Serum 1227 ***			*** Serum 1228 ***		
3 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	33%	100%	B13	50%	100%	B18	50%	100%	B35	50%	100%
B18	33%	100%	B41	50%	100%	B35	50%	100%	B44	50%	100%
B35	33%	100%	B44	50%	100%	B45	50%	100%	B45	50%	100%
B44	33%	100%	B45	50%	100%	B49	50%	100%	B49	50%	100%
B45	33%	100%	B47	50%	100%	B50	50%	100%	B50	50%	100%
B49	33%	100%	B49	50%	100%	B51	50%	100%	B52	50%	100%
B50	33%	100%	B50	50%	100%	B52	50%	100%	B53	50%	100%
B51	33%	100%	B60	50%	100%	B53	50%	100%	B62	50%	100%
B52	33%	100%	B61	50%	100%	B62	50%	100%	B63	50%	100%
B53	33%	100%				B63	50%	100%	B71	50%	100%
B62	33%	100%				B71	50%	100%	B72	50%	100%
B71	33%	100%				B72	50%	100%	B75	50%	100%
B72	33%	100%				B73	50%	100%	B77	50%	100%
B75	33%	100%				B75	50%	100%			
B77	33%	100%				B77	50%	100%			
B78	33%	100%				B78	50%	100%			

Method: Flow Cytometry											
*** Serum 1225 ***			*** Serum 1226 ***			*** Serum 1227 ***			*** Serum 1228 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no specificities assigned			no specificities assigned			no specificities assigned			no specificities assigned		

**Table 19. Summary of the 558<sup>th</sup> Serum Exchange (Serum #1225-1228) by Luminex - class I**

Method: Luminex											
*** Serum 1225 ***			*** Serum 1226 ***			*** Serum 1227 ***			*** Serum 1228 ***		
29 typing Labs			29 typing Labs			29 typing Labs			28 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B35	100%	100%	B13	100%	100%	A68	100%	100%	A1	100%	100%
B44	100%	100%	B41	100%	100%	B18	100%	100%	A23	100%	100%
B45	100%	100%	B44	100%	100%	B35	100%	100%	A43	100%	100%
B49	100%	100%	B45	100%	100%	B37	100%	100%	A80	100%	100%
B50	100%	100%	B49	100%	100%	B42	100%	100%	B13	100%	100%
B53	100%	100%	B50	100%	100%	B45	100%	100%	B35	100%	100%
B56	100%	100%	B47	97%	100%	B46	100%	100%	B45	100%	100%
B13	97%	100%	B60	97%	100%	B49	100%	100%	B46	100%	100%
B18	97%	100%	B76	97%	100%	B50	100%	100%	B49	100%	100%
B41	97%	100%	B71	97%	80%	B51	100%	100%	B50	100%	100%
B57	97%	100%	B62	97%	67%	B53	100%	100%	B53	100%	100%
B58	97%	100%	B61	93%	100%	B55	100%	100%	B55	100%	100%
B60	97%	100%	B82	90%	100%	B56	100%	100%	B56	100%	100%
B62	97%	100%	B72	90%	83%	B67	100%	100%	B58	100%	100%
B63	97%	100%	B46	90%	80%	B57	100%	90%	B67	100%	100%
B71	97%	100%	B73	86%	75%	B7	100%	71%	B44	100%	90%
B72	97%	100%	B35	86%	71%	B38	97%	100%	A29	100%	85%
B75	97%	100%	Cw16	83%	67%	B41	97%	100%	A36	100%	83%
B76	97%	100%	Cw10	79%	100%	B52	97%	100%	B37	96%	100%
B77	97%	100%	B75	79%	88%	B54	97%	100%	B38	96%	100%
B37	93%	100%	B39	79%	80%	B58	97%	100%	B41	96%	100%
B38	93%	100%	Cw12	79%	50%	B62	97%	100%	B51	96%	100%
B47	93%	100%	Cw1	79%	46%	B63	97%	100%	B52	96%	100%
B51	93%	100%	Cw8	76%	100%	B65	97%	100%	B57	96%	100%
B52	93%	100%	B48	76%	80%	B71	97%	100%	B62	96%	100%
B55	93%	100%	B64	76%	50%	B72	97%	100%	B63	96%	100%
B59	93%	100%	Cw9	72%	100%	B75	97%	100%	B71	96%	100%
B61	93%	100%	A1	72%	67%	B76	97%	100%	B72	96%	100%
B78	93%	100%	B78	69%	75%	B77	97%	100%	B75	96%	100%
B46	86%	100%	B18	69%	50%	B8	97%	100%	B76	96%	100%
B54	86%	100%	Cw14	59%	100%	A25	97%	83%	B77	96%	100%
A24	83%	100%	A23	55%	100%	B59	93%	100%	Cw6	96%	100%
B67	83%	100%	Cw7	41%	100%	B60	93%	100%	A25	93%	83%
B48	79%	100%	A34	41%	50%	B64	93%	100%	A24	93%	69%
B64	79%	100%	A24	31%	50%	B61	93%	89%	B78	89%	100%



**Table 19. Summary of the 558<sup>th</sup> Serum Exchange (Serum #1225-1228) by Luminex - class I**

Method: Luminex - cont.											
*** Serum 1225 ***			*** Serum 1226 ***			*** Serum 1227 ***			*** Serum 1228 ***		
29 typing Labs			29 typing Labs			29 typing Labs			29 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B39	76%	100%	B65	24%	100%	A34	93%	75%	Cw10	89%	100%
A23	69%	100%	B27	21%	50%	B48	90%	100%	Cw18	89%	100%
B8	66%	100%				B78	90%	100%	Cw5	89%	100%
Cw10	66%	100%				Cw10	90%	100%	Cw9	89%	100%
Cw9	66%	100%				Cw4	90%	100%	A11	86%	100%
A2	55%	100%				Cw9	90%	100%	B39	86%	100%
A69	55%	100%				A33	90%	90%	B42	86%	100%
B65	55%	100%				B39	86%	100%	B59	86%	100%
Cw4	52%	100%				B81	86%	80%	B82	86%	100%
B42	48%	100%				A66	83%	100%	Cw2	86%	100%
A68	45%	100%				B73	83%	100%	Cw4	86%	100%
Cw15	45%	100%				B82	83%	100%	Cw17	82%	100%
A25	38%	100%				A69	76%	100%	A26	82%	80%
A43	34%	100%				B27	76%	67%	A68	79%	100%
Cw5	31%	100%				Cw18	66%	100%	B27	79%	100%
A29	31%	50%				A26	66%	75%	Cw15	79%	100%
A34	31%	50%				Cw6	62%	100%	A34	71%	100%
A2403	28%	100%				B13	52%	100%	A66	71%	70%
B3901	28%	100%				Cw1	45%	100%	Cw1	64%	100%
A66	24%	100%				B2708	41%	100%	Cw14	64%	100%
Cw14	24%	100%				Cw15	34%	100%	B61	61%	75%
A203	21%	100%				A6601	31%	100%	B60	46%	100%
A6601	21%	100%				A6602	28%	100%	A33	46%	67%
Cw1	21%	100%				B3901	24%	100%	B47	43%	100%
						Bw6	24%	100%	A6601	39%	100%
						Cw14	24%	100%	B2708	39%	100%
									B48	39%	100%
									A1101	32%	100%
									A1102	32%	100%
									A31	29%	100%
									B3901	25%	100%
									B54	25%	100%

**Table 20. Summary of the 558<sup>th</sup> Serum Exchange (Serum #1225-1228) by ELISA and C1q- class I**

Method: ELISA											
<b>*** Serum 1225 ***</b>			<b>*** Serum 1226 ***</b>			<b>*** Serum 1227 ***</b>			<b>*** Serum 1228 ***</b>		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: C1q											
<b>*** Serum 1225 ***</b>			<b>*** Serum 1226 ***</b>			<b>*** Serum 1227 ***</b>			<b>*** Serum 1228 ***</b>		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B35	100%	100%	B13	100%	100%	B18	100%	100%	A1	100%	100%
B49	100%	100%	B41	100%	100%	B35	100%	100%	B13	100%	100%
B50	100%	100%	B44	100%	100%	B37	100%	100%	B35	100%	100%
B51	100%	100%	B45	100%	100%	B39	100%	100%	B45	100%	100%
B53	100%	100%	B47	100%	100%	B49	100%	100%	B46	100%	100%
B62	100%	100%	B49	100%	100%	B50	100%	100%	B49	100%	100%
B71	100%	100%	B50	100%	100%	B51	100%	100%	B50	100%	100%
B72	100%	100%	B60	100%	100%	B52	100%	100%	B51	100%	100%
B13	50%	100%	B61	100%	100%	B53	100%	100%	B52	100%	100%
B45	50%	100%	B76	100%	100%	B54	100%	100%	B53	100%	100%
B78	50%	100%				B56	100%	100%	B56	100%	100%
						B62	100%	100%	B57	100%	100%
						B63	100%	100%	B58	100%	100%
						B71	100%	100%	B62	100%	100%
						B72	100%	100%	B63	100%	100%
						B75	100%	100%	B71	100%	100%
						B76	100%	100%	B72	100%	100%
						B77	100%	100%	B75	100%	100%
						B78	100%	100%	B76	100%	100%
						Cw4	100%	100%	B77	100%	100%
						B38	50%	100%	B78	100%	100%
						B46	50%	100%	Cw10	100%	100%
						B48	50%	100%	Cw9	100%	100%
						B8	50%	100%	A23	50%	100%
						Cw10	50%	100%	A24	50%	100%
						Cw9	50%	100%	B37	50%	100%
									B41	50%	100%
									B44	50%	100%

**Table 21. Summary of the 558<sup>th</sup> Serum Exchange (Serum #1225-1228) by NIH-Extended, Antiglobulin, and Other - class II**

Method: NIH-Extended											
<b>*** Serum 1225 ***</b>			<b>*** Serum 1226 ***</b>			<b>*** Serum 1227 ***</b>			<b>*** Serum 1228 ***</b>		
1 typing Lab			1 typing Lab			1 typing Lab			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assigned			no antigens assigned			no antigens assigned			DR17	50%	100%
									DR18	50%	100%
									DR52	50%	33%

Method: Antiglobulin											
<b>*** Serum 1225 ***</b>			<b>*** Serum 1226 ***</b>			<b>*** Serum 1227 ***</b>			<b>*** Serum 1228 ***</b>		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: Other											
<b>*** Serum 1225 ***</b>			<b>*** Serum 1226 ***</b>			<b>*** Serum 1227 ***</b>			<b>*** Serum 1228 ***</b>		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
DR17	50%	100%	DR7	50%	100%	DQ4	50%	100%	DR52	50%	100%
DR18	50%	100%	DR9	50%	100%	DQ8	50%	100%			
						DQ9	50%	100%			
						DR11	50%	100%			
						DR12	50%	100%			
						DR13	50%	100%			
						DR14	50%	100%			
						DR17	50%	100%			
						DR18	50%	100%			
						DR8	50%	100%			

**Table 22. Summary of the 558<sup>th</sup> Serum Exchange (Serum #1225-1228) by Flow Cytometry and C1q - class II**

Method: Flow Cytometry											
<b>*** Serum 1225 ***</b>			<b>*** Serum 1226 ***</b>			<b>*** Serum 1227 ***</b>			<b>*** Serum 1228 ***</b>		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assigned			no antigens assigned			no antigens assigned			no antigens assigned		

Method: C1q											
<b>*** Serum 1225 ***</b>			<b>*** Serum 1226 ***</b>			<b>*** Serum 1227 ***</b>			<b>*** Serum 1228 ***</b>		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
NT			NT			DQ4	100%	100%	NT		
						DR8	100%	100%			
						DR12	50%	100%			

**Table 23. Summary of the 558<sup>th</sup> Serum Exchange (Serum #1225-1228) by Luminex - class II**

Method: Luminex											
<b>*** Serum 1225 ***</b>			<b>*** Serum 1226 ***</b>			<b>*** Serum 1227 ***</b>			<b>*** Serum 1228 ***</b>		
27 typing Labs			27 typing Labs			27 typing Labs			26 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
DR17	93%	100%	DR7	93%	100%	DQ4	100%	100%	DR17	92%	100%
DR18	93%	100%	DR9	93%	100%	DR12	100%	100%	DR18	92%	100%
DR13	72%	100%	NEG	7%	100%	DR8	100%	100%	DR52	85%	44%
DR52	72%	83%				DR11	96%	100%	DR13	35%	50%
DR14	59%	100%				DR13	96%	92%	DR14	31%	100%
DQ2	37%	40%				DR14	96%	85%	DR11	27%	100%
DR11	26%	100%				DQ8	93%	100%	DQA1*05	19%	100%
DR12	19%	100%				DR18	93%	100%			
DPw6	11%	100%				DQ9	93%	87%			
DQA1*05	11%	100%				DR17	93%	62%			
DR1404	11%	100%				DQ7	52%	52%			
DQ4	11%	50%				DQA1*05	48%	100%			
NEG	7%	100%				DQA1*06	41%	100%			
						DQA1*04	40%	100%			
						DR1404	19%	100%			
						DQA1*03	15%	100%			
						DQ3	11%	100%			
						DR1403	11%	100%			
						DR3	11%	100%			
						DR52	11%	100%			
						DQ2	11%	20%			

**Table 24. Individual laboratory results for Serum #1225-1228 by NIH-Standard and NIH-Extended - class I**

Investigator	**** Serum 1225 ****							**** Serum 1226 ****					**** Serum 1227 ****					**** Serum 1228 ****							Method			
	% POS	B53	B35	B49	B44	B51	Other	% POS	B44	B45				Other	% POS	B35	B51										Other	
Fort, Marylise	NT							NT							NT													STD
Vasilescu, Rodica	42	+	+	+	+	+	B45	25	+	+			B13	58	+	+										B49,B57	STD	
Watson, Narelle	25	+	+				B62	33	+	+				30	+	+										B62,B75	STD	

STD = NIH-Standard

Investigator	**** Serum 1225 ****							**** Serum 1226 ****						**** Serum 1227 ****						**** Serum 1228 ****								Method			
	% POS	B49	B50	B62	B35	B44	Other	% POS	B44	B50	B49	B41	B45	Other	% POS	B50	B51	B62	B71	B72	Other	% POS	B57	B62	B63	B46	B75		B76	B58	Other
Hamdi, Nuha	NT							NT							NT							93	+	+	+	+	+	+	+	Cw4,Cw6,A24>	EXT
Lardy, N.M.	71	+	+	+	+	+	B60,B51,B53>	29	+	+	+		+		48	+	+	+	+	+	B35,B53,B75	21	+	+	+				+		EXT
Reed, Elaine F. PhD	58	+	+	+			Cw4,B70	31	+	+	+	+			55	+	+	+	+	+	B18,B52,Cw4	25	+	+	+	+	+	+			EXT

EXT = NIH-Extended

**Table 25. Individual laboratory results for Serum #1225-1228 by Antiglobulin - class I**

**** Serum 1225 ****																										
Investigator	% POS	B44	B13	B35	B45	B49	B53	B51	B50	B61	B62	B72	B75	B78	A24	B41	B42	B46	B47	B52	B60	B63	B39	B56	Other	Method
Cecka, J. Michael P	87	+	+	+	+	+	+	+	+	+	+	+	+	+		+			+	+	+	+	+		B57	Antiglobulin
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+			+	+							B18	Antiglobulin
Hamdi, Nuha	98	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		Cw4,A2,B48,A66>	Antiglobulin
McCluskey, James	58	+		+											+											Antiglobulin
Vasilescu, Rodica	50	+	+	+	+	+	+	+						+											B70	Antiglobulin

**** Serum 1226 ****																											
Investigator	% POS	B44	B45	B49	B13	B50	A23	B41	B47	B60	B61	B39	A34												Other	Method	
Cecka, J. Michael P	52	+	+	+	+	+		+	+	+	+	+														B51	Antiglobulin
Hahn, Amy B. PhD		+	+	+		+	+						+													B51	Antiglobulin
Hamdi, Nuha	53	+	+	+	+	+	+	+	+	+	+	+	+													A24,B48,B78,B62 >	Antiglobulin
McCluskey, James	30	+																								Antiglobulin	
Vasilescu, Rodica	29	+	+	+	+																				B40	Antiglobulin	

**** Serum 1227 ****																															
Investigator	% POS	B51	B18	B35	B53	B62	B78	B42	B50	B52	B60	B63	B64	A33	A66	B37	B38	B39	B41	B45	B46	B49	B56	B57	B61	B7	B72	B75	B8	Other	Method
Cecka, J. Michael P	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		Antiglobulin
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A31,A36,A80	Antiglobulin
Hamdi, Nuha	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,Cw6,B48,B13 >	Antiglobulin
McCluskey, James	43	+		+		+																								Antiglobulin	
Vasilescu, Rodica	42	+	+	+	+		+																						B15,B70	Antiglobulin	

**** Serum 1228 ****																													
Investigator	% POS	B49	B57	B62	B46	B63	B75	A1	B13	B35	B37	B45	B50	B52	B55	B56	B71	B72	B78	B44	B51	B53					Other	Method	
Cecka, J. Michael P	80	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+							Antiglobulin
Hahn, Amy B. PhD		+	+	+		+	+																					B70,B81	Antiglobulin
Hamdi, Nuha	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					Cw4,Cw6,A11,B60 >	Antiglobulin	
McCluskey, James	29			+	+		+																						Antiglobulin
Vasilescu, Rodica	25	+	+																+								B15,B22	Antiglobulin	

**Table 26. Individual laboratory results for Serum #1225-1228 by Other and Flow Cytometry - class I**

Investigator	**** Serum 1225 ****															**** Serum 1226 ****											Method			
	% POS	A2	B18	B35	B44	B45	B49	B50	B51	B52	B53	B62	B71	B72	B75	B77	B78	Other	% POS	B13	B41	B44	B45	B47	B49	B50		B60	B61	Other
Liu, Chang MD, PhD	98																	75												Other-LMX Phenotype
Mayne, Elizabeth		+																NT											Other	
Reed, Elaine F. PhD	92		+	+	+	+	+	+	+	+	+	+	+	+	+	+		58	+	+	+	+	+	+	+	+	+		Other-LMX PRA	
Eckels/CPMC,	95																	96											Flow cytometry	

Investigator	**** Serum 1227 ****															**** Serum 1228 ****											Method					
	% POS	B18	B35	B45	B49	B50	B51	B52	B53	B62	B63	B71	B72	B73	B75	B77	B78	Other	% POS	B35	B44	B45	B49	B50	B52	B53		B62	B63	B71	B72	B75
Liu, Chang MD, PhD	100																		100												Other-LMX Phenotype	
Mayne, Elizabeth																			NT												Other	
Reed, Elaine F. PhD	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		96	+	+	+	+	+	+	+	+	+	+	+	+	Other-LMX PRA	
Eckels/CPMC,	99																		68												Flow cytometry	



**Table 27. Individual laboratory results for Serum #1225 by Luminex - class I**

		*** Serum 1225 ***																																								
Investigator	% POS	B35	B44	B45	B49	B50	B53	B56	B13	B18	B41	B57	B58	B60	B62	B63	B71	B72	B75	B76	B77	B37	B38	B47	B51	B52	B55	B59	B61	B78	B46	B54	A24	B67	B48	B64	B39	Other	Method			
Al-Attas, Rabab A. I		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A2,A23,A69 >	LMX		
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A23,Cw10,Cw9,A2403 >	LMX		
Bengochea, Carrett	52	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82,B8,A2403,B3901	LMX			
Cecka, J. Michael F	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX			
Chen, Dong-Feng F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A203,A2,A25 >	LMX		
Colombe, Beth W. I	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Bw4	LMX			
Daniel, Dolly	34	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A2,B40,B15 >	LMX			
Du, Keming	47	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw10,Cw9	LMX			
Dunckley, Heather	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A203,A2,A66 >	LMX		
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2,A23,A68,A69 >	LMX		
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A2,A25,A23 >	LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2,A23,A69,B65 >	LMX		
Hamdi, Nuha	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A2,A66,A25 >	LMX		
Hogan, Patrick	36	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82	LMX		
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A2,A66,A25,A*29:02,A*34:01>	LMX		
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX		
Liu, Chang MD, PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A23,B65,B8,Cw10 >	LMX	
Mayne, Elizabeth	46	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A2,B40,B15 >	LMX		
McCluskey, James		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A2,A66,A25,A*29:02,A34:01>	LMX		
Pancoska, Carol PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A2,A34,A23 >	LMX	
Permpikul, Vejbaes	51	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A23,Cw10,Cw9 >	LMX		
Pule, Ziningi	14	+	+	+	+	+	+	+																															B15,B16,Bw4,Bw6	LMX		
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A2,A66,A29,A*34:01 >	LMX	
Sacchi, Nicoletta		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4	LMX	
V.Brouard, M.Tonye	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A203,A25,A34 >	LMX	
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A203,A2,A25 >	LMX	
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,A2,A66,A25 >	LMX	
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Cw4,Cw6,A2,A66 >	LMX
Xu, Ri		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8,B12C,B5C,B8C >	LMX	





**Table 29. Individual laboratory results for Serum #1227 by Luminex - class I (cont.)**

**** Serum 1227 ****																Method
Investigator	A69	B27	Cw18	A26	Cw6	B13	Cw1	B2708	Cw15	A6601	A6602	B3901	Bw6	Cw14	Other	
Al-Attas, Rabab A. M	+	+	+	+	+	+	+								Cw6,B13,A26,Cw1 >	LMX
Arnold, Paula PhD	+	+	+					+		+	+	+			B8101,Cw18,B2708,B7801 >	LMX
Bengochea, Carretto & Cecka, J. Michael P	+	+		+								+			B703,B2708,B3901	LMX
Chen, Dong-Feng P	+	+	+	+	+	+	+	+	+	+	+				Cw6,B13,A26,B8101 >	LMX
Colombe, Beth W. F	+	+	+	+	+								+		Cw6,A26,Bw6,Cw18	LMX
Daniel, Dolly		+						+		+	+	+			B40,B15,B70,B21 >	LMX
Du, Keming	+	+	+		+										Cw6,Cw18	LMX
Dunckley, Heather	+		+	+	+	+	+	+	+	+	+			+	Cw6,B13,A26,A32 >	LMX
Eckels/CPMC,	+			+				+		+	+				A26,B2708,A6601,A6602	LMX
Fort, Marylise	+	+	+	+	+	+	+		+					+	Cw6,B13,A26,Cw1 >	LMX
Hahn, Amy B. PhD	+	+	+	+	+	+	+		+				+	+	Cw6,B13,A26,Bw6 >	LMX
Hamdi, Nuha	+	+	+	+	+	+	+		+						Cw6,B13,A26,Cw1 >	LMX
Hogan, Patrick		+											+		Bw6	LMX
Holdsworth, Rhonda	+	+	+	+	+	+	+		+						Cw6,B13,A26,Cw1 >	LMX
Lardy, N.M.								+							Cw3,B2708	LMX
Liu, Chang MD, PhD	+		+	+	+	+	+	+							Cw6,B13,A26,Cw1 >	LMX
Mayne, Elizabeth		+						+		+	+	+	+		B40,B15,B703,B14 >	LMX
McCluskey, James	+	+	+	+	+	+	+		+					+	Cw6,B13,A26,Cw1 >	LMX
Pancoska, Carol Ph	+	+	+	+	+	+	+								Cw6,B13,A26,Cw1 >	LMX
Permpikul, Vejbaesy	+	+	+		+										Cw6,Cw18	LMX
Pule, Ziningi	+	+		+									+		A24,B40,B15,A26 >	LMX
Reed, Elaine F. PhD	+	+	+	+	+	+									Cw6,B13,A26,Cw18	LMX
Sacchi, Nicoletta		+														LMX
V.Brouard, M.Tonye	+		+	+	+	+		+		+	+	+			Cw6,B13,A26,B8101 >	LMX
Vasilescu, Rodica	+	+	+	+	+	+	+	+	+	+	+	+		+	Cw6,A11,B13,A26 >	LMX
Vather/JHB,	+	+	+	+	+	+	+		+				+	+	Cw6,A11,B13,A26 >	LMX
Vather/Pinetown,	+	+	+	+	+	+	+		+				+	+	Cw6,A11,B13,B47 >	LMX
Xu, Ri								+		+		+			B12C,B5C,B8C,B7C >	LMX



**Table 30. Individual laboratory results for Serum #1228 by Luminex - class I (cont.)**

**** Serum 1228 ****																	Method						
Investigator	A26	A68	B27	Cw15	A34	A66	Cw1	Cw14	B61	B60	A33	B47	A6601	B2708	B48	A1101		A1102	A31	B3901	B54	Other	
Al-Attas, Rabab A. M	+	+	+	+	+	+	+	+	+	+	+	+			+						+	B60,B61,B48,B47 >	LMX
Arnold, Paula PhD			+	+		+	+							+	+		+			+		Cw1,B2708,B7801,A1101,A*24:02 >	LMX
Bengochea, Carrette															+					+		B2708,B3901	LMX
Cecka, J. Michael P	+	+	+		+	+																	LMX
Chen, Dong-Feng P	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+		B60,B61,B48,B47 >	LMX
Colombe, Beth W. F	+	+	+	+	+	+	+	+	+													B61,Bw4,Cw1,Cw14	LMX
Daniel, Dolly	+	+	+	+		+		+						+	+		+	+			+	A9,B15,B70,A10 >	LMX
Du, Keming	+	+	+	+	+	+	+	+	+		+											B61,A33,Cw1,Cw14	LMX
Dunckley, Heather	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B61,B48,B47 >	LMX
Eckels/CPMC,	+	+		+	+									+	+							B2708,A6601	LMX
Fort, Marylise																							LMX
Hahn, Amy B. PhD	+	+	+	+	+	+	+	+	+	+	+	+								+		B60,B61,B47,A31 >	LMX
Hamdi, Nuha	+	+	+	+	+	+	+	+	+	+	+	+			+							B60,B61,B48,B47 >	LMX
Hogan, Patrick						+								+			+	+				A1101,A1102,A6601	LMX
Holdsworth, Rhonda	+	+	+	+	+	+	+	+	+	+	+	+			+					+	+	B60,B61,B48,B47,A*24:02,A*33:03 >	LMX
Lardy, N.M.						+								+								Cw3,B2708	LMX
Liu, Chang MD, PhD	+	+	+	+	+		+	+	+					+								B61,Cw1,Cw14,A6601	LMX
Mayne, Elizabeth	+	+	+	+		+									+		+	+		+		B15,Cw3,B2708,A1101 >	LMX
McCluskey, James	+	+	+	+	+	+	+	+	+	+	+	+			+						+	B60,B61,B48,B47,A*24:02,A*33:03 >	LMX
Pancoska, Carol Ph	+	+	+	+	+	+	+	+	+	+	+	+										B60,B61,A33,Cw1 >	LMX
Permpikul, Vejbaesy	+	+	+	+	+	+	+	+	+	+	+	+			+						+	B60,B61,B48,B47 >	LMX
Pule, Ziningi	+	+	+		+	+					+									+		B15,A31,A33,Bw4 >	LMX
Reed, Elaine F. PhD	+	+	+	+	+	+	+	+	+	+					+							B60,B61,B48,Cw1,A*24:02 >	LMX
Sacchi, Nicoletta				+	+																		LMX
V.Brouard, M.Tonye	+	+	+	+	+		+	+	+			+	+	+		+	+			+		B61,B47,Cw1,Cw14 >	LMX
Vasilescu, Rodica	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B61,B48,B47 >	LMX
Vather/JHB,	+	+	+	+	+		+	+	+	+	+	+	+		+							B60,B61,B48,B47 >	LMX
Vather/Pinetown,	+	+	+	+	+	+	+	+	+	+	+	+			+					+	+	B60,B61,B48,B47 >	LMX
Xu, Ri	+													+	+		+	+				Cw403,B12C,B5C,B8C >	LMX



**Table 32. Individual laboratory results for Serum #1225 - #1228 by various methods - class II**

		**** Serum 1225 ****					**** Serum 1226 ****					**** Serum 1227 ****										**** Serum 1228 ****								
Investigator	% POS				Other	% POS			Other	% POS														% POS	DR17	DR18	DR52		Other	Method
Hamdi, Nuha	NT					NT				NT														26	+	+	+			EXT
Reed, Elaine F. PhD	U					U				U														58						EXT

EXT = NIH-Extended

		**** Serum 1225 ****					**** Serum 1226 ****				**** Serum 1227 ****											**** Serum 1228 ****							
Investigator	% POS	DR17	DR18	DR13	DR14	Other	% POS	DR7	DR9	Other	% POS	DR17	DR18	DQ4	DQ8	DQ9	DR11	DR12	DR13	DR14	DR8	Other	% POS					Other	Method
Hamdi, Nuha	31%	+	+	+	+	DR52,DQ2	31	+	+		66	+	+	+	+	+	+	+	+	+	+	+	DQ7,DQ2	NT					Antiglobulin

		**** Serum 1225 ****					**** Serum 1226 ****				**** Serum 1227 ****											**** Serum 1228 ****							
Investigator	% POS	DR17	DR18			Other	% POS	DR7	DR9	Other	% POS	DR17	DR18	DQ4	DQ8	DQ9	DR11	DR12	DR13	DR14	DR8	Other	% POS	DR52				Other	Method
Liu, Chang MD, PhD	40						29				77												31						LMX Phenotype
Reed, Elaine F. PhD	27	+	+				20	+	+		80	+	+	+	+	+	+	+	+	+	+		87	+					LMX PRA

		**** Serum 1225 ****					**** Serum 1226 ****				**** Serum 1227 ****											**** Serum 1228 ****							
Investigator	% POS					Other	% POS			Other	% POS	DQ4	DR8	DR12									Other	% POS				Other	Method
Eckels/CPMC,	66						27				78													68					FC

FC = Flow cytometry

		**** Serum 1225 ****					**** Serum 1226 ****				**** Serum 1227 ****											**** Serum 1228 ****							
Investigator	% POS					Other	% POS			Other	% POS	DQ4	DR8	DR12									Other	% POS				Other	Method
Colombe, Beth W. F	NT						NT				7	+	+	+										NT					C1q
Liu, Chang MD, PhD	NT						NT					+	+											NT					C1q

U = undetermined

NT = not typed



**Table 33. Individual laboratory results for Serum #1225 - #1226 by Luminex - class II**

Investigator	**** Serum 1225 ****										**** Serum 1226 ****				Method
	% POS	DR17	DR18	DR13	DR52	DR14	DQ2	DR11	DR12	Other	% POS	DR7	DR9	Other	
Al-Attas, Rabab A. M		+	+	+	+	+				Other DPw6		+	+		LMX
Arnold, Paula PhD		+	+	+	+							+	+		LMX
Bengochea, Carrette	0										0				LMX
Cecka, J. Michael P	31	+	+								0				LMX
Chen, Dong-Feng P		+	+	+	+	+		+	+			+	+		LMX
Colombe, Beth w. P	18	+	+							DQ4	25	+	+		LMX
Daniel, Dolly	4	+	+	+	+	+	+	+		DR3,DR6,DR1403,DR1404 >	2	+	+		LMX
Du, Keming	16	+	+	+	+	+	+			DQ4,DP13	4	+	+	DP14	LMX
Dunckley, Heather	47	+	+	+	+	+				DPw6	25	+	+		LMX
Eckels/CPMC,		+	+	+	+							+	+		LMX
Fort, Marylise		+	+	+	+	+	+					+	+	DR10,DR17,DR18,DPw6	LMX
Hahn, Amy B. PhD		+	+									+	+		LMX
Hamdi, Nuha	31	+	+	+	+	+	+				31	+	+		LMX
Hogan, Patrick	3	+	+								2	+	+		LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	DQ5,DPw6,DP11,DP13 >		+	+		LMX
Liu, Chang MD, PhD		+	+									+	+		LMX
Mayne, Elizabeth	7	+	+	+	+	+	+	+		DR3,DR5,DR6,DR1404	2	+	+		LMX
McCluskey, James		+	+	+	+	+	+	+	+			+	+		LMX
Pancoska, Carol Ph		+	+	+	+	+				DQ4		+	+		LMX
Permpikul, Vejbaesy	9	+	+	+	+	+					4	+	+		LMX
Pule, Ziningi	0										2	+	+		LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	DQB1*06:02		+	+		LMX
Sacchi, Nicoletta		+	+									+	+		LMX
V.Brouard, M.Tonye	12	+	+								31	+	+		LMX
Vather/JHB,		+	+	+	+	+	+			DQA1*05		+	+		LMX
Vather/Pinetown,		+	+	+	+	+	+	+	+	DQ5,DQ6,DQA1*05		+	+	DQ5	LMX
Xu, Ri		+	+	+	+	+				DR1403,DR1404		+	+		LMX

**Table 34. Individual laboratory results for Serum #1227 - #1228 by Luminex - class II**

Investigator	**** Serum 1227 ****													**** Serum 1228 ****							Method				
	% POS	DQ4	DR12	DR8	DR11	DR13	DR14	DQ8	DR18	DQ9	DR17	DQ7	DQA1*05	DQA1*06	DQA1*04	Other	% POS	DR17	DR18	DR52		DR13	DR14	DR11	Other
Al-Attas, Rabab A. M		+	+	+	+	+	+	+	+	+	+	+						+	+	+					LMX
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+					+	+	+					LMX
Bengochea, Carrette	29	+	+	+	+	+	+	+	+	+	+	+				DR1404	0								LMX
Cecka, J. Michael P	60	+	+	+	+	+	+	+	+	+	+	+					26	+	+						LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+					+	+	+	+	+	+		LMX
Colombe, Beth w. P	73	+	+	+	+	+	+	+	+	+	+	+					18	+	+						LMX
Daniel, Dolly	29	+	+	+	+	+	+	+	+	+	+	+				DR3,DR5,DR6,DR1403 >	4	+	+	+	+	+	+	DR3,DR6,DR1403	LMX
Du, Keming	24	+	+	+	+	+	+	+	+	+	+	+					7	+	+	+	+			DPw1,DPw5	LMX
Dunckley, Heather	81	+	+	+	+	+	+	+	+	+	+	+	+	+			22	+	+	+					LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+				+	+	+					LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+				DQ2	NT								LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+					+	+	+					LMX
Hamdi, Nuha	66	+	+	+	+	+	+	+	+	+	+	+				DQ2	26	+	+	+					LMX
Hogan, Patrick	29	+	+	+	+	+	+	+	+	+	+	+				DR1403,DR1404	4	+	+	+					LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	DR52,DP15		+	+	+	+	+	+	DR7,DPw1,DPw5	LMX
Liu, Chang MD, PhD		+	+	+	+	+	+	+	+	+	+	+	+	+				+	+	+					LMX
Mayne, Elizabeth	30	+	+	+	+	+	+	+	+	+	+	+				DR3,DR5,DR6,DR1404 >	29							DR53,DQ2,DQ3,DQ4 >	LMX
McCluskey, James		+	+	+	+	+	+	+	+	+	+	+	+	+				+	+	+	+	+	+	DQA1*05	LMX
Pancoska, Carol Ph		+	+	+	+	+	+	+	+	+	+	+	+	+				+	+	+	+	+	+		LMX
Permpikul, Vejbaesy	27	+	+	+	+	+	+	+	+	+	+	+	+	+		DQA1*03	14	+	+	+				DQA1*05	LMX
Pule, Ziningi	35	+	+	+	+	+	+									DR3,DQ3,DQ6	5							DR3	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+				+	+	+	+	+			LMX
Sacchi, Nicoletta		+	+	+	+	+	+	+	+	+	+	+						+	+	+					LMX
V.Brouard, M.Tonye	14	+	+	+													31	+	+	+					LMX
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+		DR4,DR52,DQ2,DQA1*02 >		+	+	+	+	+	+	DQA1*05	LMX
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+		DR52,DQA1*03		+	+	+	+	+	+	DR7,DQA1*05	LMX
Xu, Ri		+	+	+	+	+	+	+	+	+	+	+				DR1403,DR1404		+	+	+					LMX